Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. Sell-side analysts expect that Viridian Therapeutics will post -4.03 earnings per share for ...

To her great cost, the Chancellor of the Exchequer has found out the hard way that painting Britain as an economic basket case undermines business confidence. In an effort to reverse six months of ...

ByInvesting.com • Jun 11, 2024 Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye ...

Miriam Helmick talks to "20/20" about that fateful day. Fifteen years ago, Miriam Helmick was sentenced to life without parole for the murder of her second husband, Colorado businessman Alan ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

- THRIVE global phase 3 clinical trial evaluated efficacy and safety of VRDN-001 in patients with active thyroid eye disease (TED) -- Conference call and webcast to be held... WALTHAM, Mass.

Check Out Our Latest Research Report on VRDN Viridian Therapeutics Trading Up 1.1 % NASDAQ VRDN opened at $19.43 on Tuesday. The company’s 50-day moving average price is $19.42 and its 200-day ...

Morning Star 30 69 Jan 23, 2025 20:00 ...

Thomas Smith’s rating is based on the promising developments and strategic positioning of Viridian Therapeutics. The company has reported favorable Phase 3 results for its lead asset ...